ReviewPLoS pathogens2020
Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020.
Review in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Cytokine and Lymphocyte Profiles in COVID-19 Patients with Cancer: Implications for Disease Severity and Clinical Outcomes.Viruses · 2026Article
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells.Nature immunology · 2023Article
- Identification of natural killer markers associated with fatal outcome in COVID-19 patients.Frontiers in cellular and infection microbiology · 2023Article
- Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics.BioImpacts : BI · 2023Review
- A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J · 2022Review
- Review
- Adaptive MHC-E restricted tissue-resident NK cells are associated with persistent low antigen load in alveolar macrophages after SARS-CoV-2 infection.Research square · 2022Article
- NK cells in SARS-CoV-2 infection.Central-European journal of immunology · 2022Review
- Plasticity of natural killer cells in pregnant patients infected with SARS-CoV-2 and their neonates during childbirth.Frontiers in immunology · 2022Article
- Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.Antiviral research · 2021Article
- Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.Human vaccines & immunotherapeutics · 2021Review
- Article
- Dysfunction of natural killer cells in end-stage kidney disease on hemodialysis.Renal replacement therapy · 2021Review
- COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review.Frontiers in psychiatry · 2021Article
- Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity.The Journal of clinical investigation · 2020Review
- Innate immunology in COVID-19-a living review. Part II: dysregulated inflammation drives immunopathology.Oxford open immunology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The COVID-19 pandemic has caused more than 575,000 deaths worldwide as of mid-July 2020 and still continues globally unabated. Immune dysfunction and cytokine storm complicate the disease, which in turn leads to the question of whether stimulation or suppression of the immune system would curb the disease. Given the varied antiviral and regulatory functions of natural killer (NK) cells, they could be potent and powerful immune allies in this global fight against COVID-19. Unfortunately, there is somewhat limited knowledge of the role of NK cells in SARS-CoV-2 infections and even in the related SARS-CoV-1 and MERS-CoV infections. Several NK cell therapeutic options already exist in the treatment of tumor and other viral diseases and could be repurposed against COVID-19. In this review, we describe the current understanding and potential roles of NK cells and other Fc receptor (FcR) effector cells in SARS-CoV-2 infection, advantages of using animals to model COVID-19, and NK cell-based therapeutics that are being investigated for COVID-19 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.